Abbott Laboratories Return on Tangible Equity 2010-2024 | ABT
Current and historical return on tangible equity values for Abbott Laboratories (ABT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Abbott Laboratories Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $5.77B | $9.02B | 74.08% |
| 2024-06-30 | $5.56B | $8.43B | 81.55% |
| 2024-03-31 | $5.63B | $7.36B | 97.30% |
| 2023-12-31 | $5.72B | $6.33B | 114.01% |
| 2023-09-30 | $5.16B | $5.14B | 118.68% |
| 2023-06-30 | $5.16B | $4.31B | 137.51% |
| 2023-03-31 | $5.80B | $4.30B | 177.48% |
| 2022-12-31 | $6.93B | $3.65B | 307.89% |
| 2022-09-30 | $7.89B | $2.75B | 583.40% |
| 2022-06-30 | $8.55B | $2.38B | 4987.76% |
| 2022-03-31 | $7.73B | $0.23B | -639.62% |
| 2021-12-31 | $7.07B | $0.05B | -320.21% |
| 2021-09-30 | $7.24B | $-1.97B | -201.05% |
| 2021-06-30 | $6.38B | $-3.14B | -131.53% |
| 2021-03-31 | $5.72B | $-3.78B | -94.14% |
| 2020-12-31 | $4.50B | $-5.53B | -61.35% |
| 2020-09-30 | $3.38B | $-6.95B | -41.37% |
| 2020-06-30 | $3.11B | $-8.07B | -36.33% |
| 2020-03-31 | $3.58B | $-8.77B | -40.10% |
| 2019-12-31 | $3.69B | $-8.92B | -39.34% |
| 2019-09-30 | $3.29B | $-8.49B | -32.88% |
| 2019-06-30 | $2.90B | $-9.53B | -26.59% |
| 2019-03-31 | $2.62B | $-10.55B | -22.29% |
| 2018-12-31 | $2.37B | $-11.47B | -18.92% |
| 2018-09-30 | $0.89B | $-12.00B | -6.69% |
| 2018-06-30 | $0.93B | $-13.02B | -7.50% |
| 2018-03-31 | $0.48B | $-13.57B | -4.20% |
| 2017-12-31 | $0.48B | $-14.40B | -4.65% |
| 2017-09-30 | $2.10B | $-8.43B | -46.38% |
| 2017-06-30 | $1.17B | $-9.00B | -359.48% |
| 2017-03-31 | $1.50B | $-9.21B | 44.78% |
| 2016-12-31 | $1.40B | $8.50B | 19.83% |
| 2016-09-30 | $1.37B | $8.41B | 21.16% |
| 2016-06-30 | $2.28B | $5.73B | 39.46% |
| 2016-03-31 | $2.45B | $5.61B | 39.46% |
| 2015-12-31 | $4.42B | $6.13B | 69.79% |
| 2015-09-30 | $4.56B | $5.63B | 74.17% |
| 2015-06-30 | $4.52B | $7.45B | 70.00% |
| 2015-03-31 | $4.20B | $6.15B | 62.46% |
| 2014-12-31 | $2.28B | $5.37B | 31.67% |
| 2014-09-30 | $1.97B | $6.85B | 23.70% |
| 2014-06-30 | $2.40B | $8.53B | 27.78% |
| 2014-03-31 | $2.41B | $8.10B | 28.81% |
| 2013-12-31 | $2.58B | $9.76B | 31.68% |
| 2013-09-30 | $3.04B | $8.14B | 48.21% |
| 2013-06-30 | $4.02B | $7.43B | 82.32% |
| 2013-03-31 | $5.27B | $7.20B | 170.94% |
| 2012-12-31 | $5.96B | $2.45B | 480.21% |
| 2012-09-30 | $6.53B | $2.44B | 1938.83% |
| 2012-06-30 | $4.89B | $0.23B | -571.14% |
| 2012-03-31 | $5.11B | $-0.15B | -359.46% |
| 2011-12-31 | $4.73B | $-1.17B | -196.08% |
| 2011-09-30 | $4.55B | $-2.34B | -131.96% |
| 2011-06-30 | $5.14B | $-2.03B | -111.53% |
| 2011-03-31 | $4.49B | $-4.12B | -85.92% |
| 2010-12-31 | $4.63B | $-5.32B | -86.34% |
| 2010-09-30 | $4.73B | $-6.97B | -152.11% |
| 2010-06-30 | $5.31B | $-4.49B | -839.83% |
| 2010-03-31 | $5.31B | $-4.66B | 579.54% |
| 2009-12-31 | $5.75B | $3.70B | 267.47% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $203.157B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $148.171B | 33.39 |
| Boston Scientific (BSX) | United States | $133.131B | 38.28 |
| EssilorLuxottica (ESLOY) | France | $113.461B | 0.00 |
| Medtronic (MDT) | Ireland | $109.010B | 16.19 |
| Haleon (HLN) | United Kingdom | $42.913B | 27.88 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.122B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.701B | 19.56 |
| ResMed (RMD) | United States | $34.955B | 28.72 |
| Terumo (TRUMY) | Japan | $29.203B | 41.24 |
| Koninklijke Philips (PHG) | Netherlands | $24.410B | 18.68 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.087B | 14.06 |
| Insulet (PODD) | United States | $18.377B | 73.18 |
| Baxter (BAX) | United States | $16.604B | 10.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.153B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.468B | 37.96 |
| Bio-Rad Laboratories (BIO) | United States | $8.977B | 30.51 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.523B | 12.83 |
| TG Therapeutics (TGTX) | United States | $4.720B | 0.00 |
| Haemonetics (HAE) | United States | $4.260B | 20.79 |
| ICU Medical (ICUI) | United States | $4.155B | 39.56 |
| Prestige Consumer Healthcare (PBH) | United States | $4.074B | 20.26 |
| Perrigo (PRGO) | Ireland | $3.716B | 10.94 |
| Envista Holdings (NVST) | United States | $3.487B | 25.97 |
| Neogen (NEOG) | United States | $3.270B | 37.72 |
| Agios Pharmaceuticals (AGIO) | United States | $3.103B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.789B | 17.89 |
| QuidelOrtho (QDEL) | United States | $2.595B | 16.70 |
| Warby Parker (WRBY) | United States | $2.344B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.332B | 56.69 |
| Green Thumb Industries (GTBIF) | United States | $1.964B | 34.37 |
| AtriCure (ATRC) | United States | $1.772B | 0.00 |
| InMode (INMD) | Israel | $1.487B | 8.94 |
| Curaleaf Holdings (CURLF) | Canada | $1.348B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.311B | 9.37 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.168B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.957B | 7.48 |
| CeriBell (CBLL) | United States | $0.916B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.888B | 29.68 |
| Capricor Therapeutics (CAPR) | United States | $0.839B | 0.00 |
| Evolus (EOLS) | United States | $0.785B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.608B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.596B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.596B | 26.47 |
| Surmodics (SRDX) | United States | $0.559B | 0.00 |
| Quanterix (QTRX) | United States | $0.424B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.404B | 0.00 |
| Valneva SE (VALN) | France | $0.370B | 0.00 |
| ZimVie (ZIMV) | United States | $0.363B | 30.63 |
| Omeros (OMER) | United States | $0.349B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.335B | 31.89 |
| Biote (BTMD) | United States | $0.330B | 7.25 |
| Sanara MedTech (SMTI) | United States | $0.323B | 0.00 |
| Cerus (CERS) | United States | $0.312B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.288B | 19.30 |
| Zynex (ZYXI) | United States | $0.249B | 52.13 |
| TerrAscend (TSNDF) | Canada | $0.243B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.229B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.219B | 15.15 |
| MacroGenics (MGNX) | United States | $0.218B | 0.00 |
| High Tide (HITI) | Canada | $0.215B | 89.00 |
| Sanuwave Health (SNWV) | United States | $0.195B | 2.74 |
| Jin Medical (ZJYL) | China | $0.188B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.162B | 0.00 |
| Brainsway (BWAY) | Israel | $0.161B | 96.70 |
| Organigram Holdings (OGI) | Canada | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.143B | 17.98 |
| TriSalus Life Sciences (TLSI) | United States | $0.126B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.106B | 0.00 |
| Fonar (FONR) | United States | $0.093B | 10.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 23.00 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.082B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.080B | 41.50 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.070B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.066B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| Exagen (XGN) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.059B | 0.00 |
| Safety Shot (SHOT) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.052B | 0.00 |
| Apyx Medical (APYX) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.026B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.011B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.17 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |